Form 4: Acadia Pharmaceuticals Director Daniel B. Soland Reports Transactions in Company Stock

Director Daniel B. Soland reports acquisition and disposal of Acadia Pharmaceuticals stock and derivative securities.

Summary

• On May 29, 2024, Daniel B. Soland, a director of Acadia Pharmaceuticals, reported transactions involving the company's stock.
• These transactions included the acquisition of 6,652 shares of common stock through the vesting of restricted stock units.
• Soland also disposed of 6,652 shares.
• Following these transactions, Soland directly owns 34,654 shares of Acadia Pharmaceuticals common stock.
• Additionally, Soland acquired 15,959 stock options with an exercise price of $14.62, expiring on May 28, 2034.
• Soland also acquired 9,387 restricted stock units that will vest on the earlier of one year following the date of grant or the next annual meeting of stockholders.
• Soland has granted power of attorney to Jennifer J. Rhodes, Peter Chae, James K. Kihara, or Martin Choy to execute Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are routine and do not indicate a strong positive or negative outlook.

Positives

• The acquisition of stock options and restricted stock units indicates confidence in the company's future performance.

Negatives

• The disposal of 6,652 shares could be interpreted negatively, although it is related to the vesting of restricted stock units.

Risks

• The value of the stock options is dependent on the future stock price of Acadia Pharmaceuticals.
• Changes in company performance or market conditions could impact the value of the holdings.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment.

Key Dates